Skip to content

Irritable Bowel Syndrome (IBS) Health Center

IBS Drug Zelnorm OK'd for Some

FDA Allows Suspended IBS Drug Zelnorm for Patients Who Meet Certain Guidelines
Font Size
A
A
A
By
WebMD Health News
Reviewed by Louise Chang, MD

(Editor’s Note: On April 2, 2008, Zelnorm’s manufacturer voluntarily discontinued Zelnorm. It is no longer available.)

July 27, 2007 -- The irritable bowel syndrome drug Zelnorm, which was taken off the U.S. market earlier this year, will be allowed for some patients under tight restrictions, the FDA announced today.

On March 30, the FDA asked Novartis, Zelnorm's maker, to suspend Zelnorm's U.S. marketing and sales because a safety analysis found a higher chance of heart attack, stroke, and unstable angina (heart/chest pain) in patients treated with Zelnorm compared with treatment with an inactive substance (placebo).

Today's FDA announcement doesn't mean that it's back to business as usual for Zelnorm.

Instead, the FDA is treating Zelnorm like an investigational new drug and restricting Zelnorm's use to the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC) in women younger than 55 who meet specific guidelines.

"These patients must meet strict criteria and have no known or pre-existing heart problems and be in critical need of this drug," the FDA's Steven Galson, MD, MPH, says in an FDA news release.

"Zelnorm will remain off the market for general use," says Galson, who directs the FDA's Center for Drug Evaluation and Research.

Investigational new drugs aren't approved drugs.

In some instances, patients with a serious or life-threatening disease or condition who are not enrolled in a clinical trial may be treated with a drug not approved by the FDA. Generally, such use is allowed within guidelines called a treatment investigational new drug protocol, when no comparable or satisfactory alternative drug or therapy is available.

When the FDA asked Novartis to take Zelnorm off the U.S. market in March, the FDA indicated that there might be patients for whom Zelnorm's benefits outweigh the risks and for whom no other treatment options were available.

At the time, the FDA committed to work with Novartis to allow access to Zelnorm for those patients through a special program. That work resulted in today's announcement.

Irritable bowel syndrome is a disorder characterized most commonly by cramping, abdominal pain, bloating, constipation, and diarrhea. IBS causes a great deal of discomfort and distress, but it does not permanently harm the intestines and does not lead to disease. For some people, however, IBS can be disabling. They may be unable to work, attend social events, or even travel short distances.

Today on WebMD

filling glass of water from faucet
Prevention strategies to try.
stomach ache
From symptoms to treatments.
 
Hand holding white tablet
Treatment options.
worried mature woman
Are they related?
 
IBS Trigger Foods
Video
Supplements for IBS What Works
Article
 
IBS Symptoms Quiz
Quiz
digestive health
Slideshow
 
gluten free diet
Slideshow
digestive myths
Slideshow
 
what causes diarrhea
Video
top foods for probiotics
Slideshow
 

WebMD Special Sections